Four proteolytic processes of myocardium, one insensitive to thiol reactive agents and thiol protease inhibitor.
Four distinct processes mediating protein degradation were identified in the Langendorff perfused rat heart. Hearts were biosynthetically labeled in vitro with [3H]leucine for 10 min. The subsequent release of [3H]leucine at 1.5-min intervals (2 mM nonradioactive leucine) was determined from 20 min to 8 h after labeling in rhythmically contracting hearts. Rapid turnover proteins were eliminated during the first 3 h; this degradation was not inhibited by insulin (5 nM) or isoproterenol (0.5 microM). However, the nontoxic thiol reactive agent diamide (100 microM) caused a complete inhibition of the [3H]leucine release from rapidly degraded proteins. After the elimination of rapidly degraded proteins at 3 h, the release of [3H]leucine was inhibited 35-40% by insulin (5 nM) or the lysosomal inhibitor chloroquine (30 microM), thereby defining a second vesicular process. The beta-agonist isoproterenol (0.5 microM) or the nonselective alpha-agonist naphazoline (100 microM) caused 30-35% proteolytic inhibitions, defining a third adrenergic-responsive process. The inhibitory effects of simultaneously combined insulin and chloroquine did not exceed the effect of either agent alone. However, the combined effects of insulin and isoproterenol were additive, inhibiting two-thirds of basal degradation. Beginning at 3 h after labeling a 75% proteolytic inhibition resulted from the thiol reactive agents diamide (100 microM) or N-ethylmaleimide (10 microM); the thiol protease active site inhibitor trans-epoxysuccinly-L-leucylamino-(4-quinidino)butane (50 microM) caused 65% inhibition. The 75% inhibition caused by diamide includes both the insulin-responsive and beta-adrenergic-responsive pathways. A novel fourth proteolytic process (25% of proteolysis) was thereby distinguished from the above three by its resistance to inhibition by insulin, adrenergic agonists, thiol reactive agents, or thiol protease inhibitor. Only the adrenergic-responsive process was correlated with changes in contractile rhythm or fibrillation.
Thorne
D P
DP
Department of Pharmacology and Toxicology, School of Medicine, Wright State University, Dayton, Ohio 45435.
Lockwood
T D
TD
D000818:Animals; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D003958:Diamide / Q000494:pharmacology*; D004351:Drug Resistance; D007328:Insulin / Q000494:pharmacology; D007930:Leucine / Q000378:metabolism; D008247:Lysosomes / Q000378:metabolism; D009206:Myocardium / Q000201:enzymology* / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism*; D051381:Rats; D013566:Sympathomimetics / Q000494:pharmacology
D015853:Cysteine Proteinase Inhibitors; D007328:Insulin; D013566:Sympathomimetics; D003958:Diamide; D010447:Peptide Hydrolases; D007930:Leucine